Press Releases

NEW YORK and BASEL, Switzerland, Jan. 22, 2020 /PRNewswire/ -- Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative therapies for the treatment of severe blood disorders, today announced that the U.S. Food and Drug Administration has granted Orphan Drug designation to ARU-1801,

BOCA RATON, Fla., Jan. 22, 2020 /PRNewswire/ -- MDVIP, the national leader in affordable healthcare, today announced the opening of two new MDVIP-affiliated primary care practices in Austin, Texas. Board certified family medicine physicians

WASHINGTON, Jan. 22, 2020 /PRNewswire/ -- National Integrated Health Associates (NIHA) has expanded the Pediatric Medical team to include Dr.

SAN DIEGO, Jan. 22, 2020 /PRNewswire/ -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, announced topline results from a 12-week, randomized, placebo-controlled study of MET409 in patients with non-alcoholic steatohepatitis (NASH). MET409 is

NEW YORK and MAINLAND, Pa., Jan. 22, 2020 /PRNewswire/ -- Palladium Equity Partners, LLC (along with its affiliates, "Palladium"), a middle market private equity firm with approximately $3 billion in assets under management, today announced that it has acquired Accupac, Inc. ("Accupac" or the "Company"), a le

Laval, QC, Jan. 22, 2020 /PRNewswire/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) ("Crescita" or the "Company"), a commercial dermatology company with manufacturing capabilities and a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, today announced t

SCOTTSDALE, Ariz., Jan. 22, 2020 /PRNewswire/ -- Axon (Nasdaq: AAXN), the global leader in connected public safety technologies, today announced that Cypress Creek Emergency Medical Services (EMS), a 9

ABBOTT PARK, Ill., Jan. 22, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter and full year ended Dec. 31, 2019.Fourth-quarter worldwide sales of $8.3 billion increased 7.1 percent on a reported basis and 8.5 percent on an organic* basis. Reported diluted

BOSTON and CARLSBAD, Calif., Jan. 22, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced positive topline results from the Phase 2 study of AKCEA-APOCIII-LRx in the treatment of patients with hyp

- Preferred shares issued in recently completed $103M financing to convert to common shares -- Gilead to become shareholder in Sierra in accordance with amendment to Purchase Agreement - VANCOUVER, Jan. 22, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on